HTG Molecular Diagnostics, Inc. (HTG) announced a leadership transition plan in which TJ Johnson, Chief Executive Officer of HTG will assume the role of Executive Chairman of the Board of Directors of HTG. John Lubniewski, President and Chief Operating Officer will succeed Mr. Johnson as Chief Executive Officer, and Dr. Ann Hanham, Ph.D. will assume the role of Lead Independent Director at the end of the first quarter 2019. Mr. Lubniewski has served as President and Chief Operating Officer since April 2018.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0025 USD | 0.00% | 0.00% | +92.31% |
2023 | Motion for De Minimus Asset Sale Approved for HTG Molecular Diagnostics, Inc. | CI |
2023 | Motion for De Minimus Asset Sale Filed by HTG Molecular Diagnostics, Inc. | CI |
1st Jan change | Capi. | |
---|---|---|
+92.31% | 5.54K | |
-16.33% | 18.62B | |
+22.02% | 1.94B | |
+0.39% | 1.68B | |
+27.15% | 1.26B | |
-10.70% | 1.03B | |
-18.27% | 938M | |
+0.66% | 783M | |
-25.07% | 628M | |
+14.62% | 535M |
- Stock Market
- Equities
- HTGMQ Stock
- News HTG Molecular Diagnostics, Inc.
- HTG Molecular Diagnostics, Inc. Announces Executive Changes